SLC2A9

Across TCGA pan-cancer cohorts, SLC2A9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC2A9 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC2A9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC2A9 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where SLC2A9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.888	.003	23	view →
LUAD	DFS	Tertile	II,III,IV	0.834	0.181	.011	11	view →
HNSC	DFS	Quartile	IV	1.000	0.600	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC2A9–CCRCC (OS)

Open the CCRCC breakdown →